#AAO22: J&J’s first look at common eye disease portfolio pads the case for PhII of gene therapynews2022-10-01T14:22:47+00:00October 1st, 2022|Endpoints News|
Landmark Amylyx OK spurs debate; Some… positive? Alzheimer’s data; Cancer trial bottleneck; Sanofi’s CRISPR bet; and morenews2022-10-01T10:00:57+00:00October 1st, 2022|Endpoints News|
#AAO22: Iveric Bio, undeterred by looming PDUFA for competitor, touts subgroup data on GA drugnews2022-09-30T21:30:51+00:00September 30th, 2022|Endpoints News|
#AAO22: In bid for first FDA nod in geographic atrophy, Apellis claims another first in eye disease fieldnews2022-09-30T21:30:33+00:00September 30th, 2022|Endpoints News|
George Church, Wyss scientists and Northpond challenge conventional RNA manufacturing with new biotechnews2022-09-30T19:28:22+00:00September 30th, 2022|Endpoints News|
BioCryst launches awareness campaign around management of rare vascular diseasenews2022-09-30T19:25:47+00:00September 30th, 2022|Endpoints News|
EMA makes new recommendations for Imbruvica, medicines with terlipressin over respiratory and cardiovascular risksnews2022-09-30T19:21:57+00:00September 30th, 2022|Endpoints News|
Updated: Alnylam reinforces APOLLO-B patisiran data before heading to the FDAnews2022-09-30T19:21:11+00:00September 30th, 2022|Endpoints News|
New inflation-linked drug rebates go into effect on Saturdaynews2022-09-30T19:15:00+00:00September 30th, 2022|Endpoints News|
European pharma group wants to create PRV-like system to spur antibiotics R&Dnews2022-09-30T18:53:12+00:00September 30th, 2022|Endpoints News|
